Barclays upgrades Nike to overweight, says ‘worst may be behind’

Barclays upgraded Nike to overweight from equal weight and raised its 12-month price target to $73 from $64, implying roughly 30% upside from current levels. Shares are down 12% YTD and 24% over the past 12 months. Analyst Adrienne Yih cited operational progress — inventory management, North America reset, margin stabilization and management discipline — as the rationale, while flagging ongoing risks from tariffs, geopolitical tensions, uncertain demand and reset risks in China/APAC and LATAM.

Analysis

The most actionable dynamic is margin and working-capital leverage rather than top-line surprise: a sustained shift from promotional to full-price sell-through and a falling inventory/sales ratio would translate into 150–300bp gross-margin tailwinds and a multi-hundred-million dollar uplift to free cash flow within 2–4 quarters. That FCF swing can be deployed into buybacks or product investments, creating a virtuous loop that supports multiple expansion even without a step-change in organic growth.

On the competitive and supply-chain side, a durable recovery in premium running/apparel volumes benefits higher-margin direct-to-consumer channels and upstream footwear manufacturers in Southeast Asia while compressing the relative returns of price-led competitors that rely on clearance-driven volume. Wholesale restocking that some call “channel stuffing” should be modeled as normalizing cadence: it will front-load revenue but only materially help margins if inventory turns accelerate beyond current baselines.

Key tail risks are asymmetric and time-staggered: an escalation in tariffs or China-related demand weakness can bite margins by ~100–250bps and push regional comps into another 2–4 quarter lull; conversely, two consecutive quarters of gross-margin improvement and inventories moving lower would be a near-term catalyst. Monitor three high-frequency readouts—inventory/sales delta, gross-margin ex-FX, and DTC sell-through velocity—to adjudicate whether the recovery is durable or a transient restock.

From a positioning lens, current investor skepticism is a convexity opportunity if you size for idiosyncratic operational risk and hedge regional exposure; use options or cross-asset pairs to capture upside while limiting drawdown from macro or tariff shocks.

Key Decisions for Investors

• Tactical long NKE equity (accumulate up to 2% NAV): begin on confirmation of two consecutive quarters of improving inventory-to-sales or sequential gross-margin expansion; target 25–35% upside over 12 months, hard stop at -12% from entry to control idiosyncratic execution risk.
• Pair trade — long NKE / short ADDYY (Adidas) dollar-neutral, 1.5% NAV gross per leg: plays US DTC/margin recovery vs. Europe/China-exposed competitor risk; expect 15–25% relative outperformance over 3–9 months, stop the pair if spread widens by 8% adverse.
• Defined-cost option: buy a 12-month NKE call spread (size 0.5% NAV) — e.g., buy LEAP call, sell higher strike to finance ~50–70% of cost — offers asymmetric upside (target >2x payout) while limiting premium decay if the recovery stalls.
• Hedge: purchase tail protection (3–6 month puts or put spread, 0.25% NAV) on China/Asia-exposed apparel names or buy S&P/consumer discretionary puts if macro consumer indicators roll over; this caps downside from tariff escalation or regional demand shock.